Lupin Ltd. should study whether excessive in-process hold times are responsible for out-of-specification results the Mumbai, India, firm has been routinely dismissing as outliers or results of laboratory error, US FDA says in a Nov. 6 warning letter that the agency published Nov. 15.
FDA also told Lupin that while it studies whether hold times are the culprit, it should go ahead and work...